In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study

Finegold, Sydney M.; Molitoris, E; Reeves, Denise; Wexler, Hannah M.

doi:10.1093/jac/28.suppl_c.25

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANAEROBIC GRAM-POSITIVE BACTERIA For anaerobic gram-positive bacteria, only MIC data have been published so far for the agents listed in Table 7 (2,4,8,9,14,25,31). Unlike the case with aerobic gram-positive bacteria, not all newer quinolones are active against anaerobes.…”

Section: Streptococcimentioning

confidence: 99%

New quinolones and gram-positive bacteria

Piddock

1994

Antimicrob Agents Chemother

108

View full text Add to dashboard Cite

Section: Streptococcimentioning

confidence: 99%

New quinolones and gram-positive bacteria

Piddock

1994

Antimicrob Agents Chemother

108

View full text Add to dashboard Cite

“…Ciprofloxacin lacked in vitro potency against many important anaerobic bacteria, but several newer quinolones looked promising [2][3][4][5][6]. Trovafloxacin was the first fluoroquinolone to receive approval from the US Food and Drug Administration for the treatment of anaerobic bacteria, such as Bacteroides fragilis, Peptostreptococcus species, and Prevotella species isolated from patients with intra-abdominal and pelvic infections [7,8].…”

mentioning

confidence: 99%

Fluoroquinolones and Anaerobes

Stein

Goldstein

2006

Clinical Infectious Diseases

View full text Add to dashboard Cite

The usefulness of fluoroquinolones for the treatment of mixed aerobic and anaerobic infections has been investigated since these agents started being used in clinical practice. Newer compounds have increased in vitro activity against anaerobes, but clinically relevant susceptibility breakpoints for these bacteria have not been established. Pharmacodynamic analyses and corroboration by new data from clinical trials have enhanced our knowledge concerning the use of fluoroquinolones to treat selective anaerobic pathogens. These studies suggest that newer agents could be useful in the treatment of several types of mixed aerobic and anaerobic infections, including skin and soft-tissue, intra-abdominal, and respiratory infections. The major concerns with expanding the use of fluoroquinolones to treat anaerobic infections have been reports of increasing resistance in Bacteroides group isolates and the impact of these antibiotics on the incidence of Clostridium difficile-associated disease.

show abstract

“…Sparfloxacin (AT-4140, RP 64206, and PD 131501) is a new fluoroquinolone agent that has an expanded spectrum of activity against aerobic and anaerobic bacteria (1,4,7). Temafloxacin, recently voluntarily removed from the market by its manufacturer, was also considered potentially useful in bite wound therapy (5,7,10). Erythromycin, while suboptimally active against Pasteurella multocida, must sometimes be used, albeit cautiously, for the treatment of bite wound infections in multidrug-allergic patients, children, and pregnant women.…”

mentioning

confidence: 99%

Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents

Goldstein¹,

Citron²

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activities of sparfloxacin, temafloxacin, ciprofloxacin, ofloxacin, clarithromycin, erythromycin, tetracycline, cephalothin, penicillin G, and amoxicillin-clavulanic acid against 173 recent clinical bite wound isolates were determined by agar dilution. Sparfloxacin was active against all strains (MIC for 90%o of strains tested, c1 ,ug/ml) except for most fusobacteria and one-third of the Prevotela spp. The other fluoroquinolones had similar activities but higher MICs, especially for streptococci. Clarithromycin was more active against many isolates including Pasteureffa mulocida than erythromycin, with MICs of .2 iLg/ml (versus 4 ,ug/mi for erythromycin).Since many laboratories are unable to perform in vitro susceptibility studies with fastidious aerobic and anaerobic bacteria, clinicians must sometimes rely on the medical literature to guide therapeutic choices, both empiric and specific, for human and animal bite wounds. Prior studies (3,6,8,9) have noted a high percentage of 3-lactamaseproducing bacteria and the emergence of resistance to commonly used antimicrobial agents in several genera of isolates obtained from bite wounds. Consequently, information about newer alternative therapeutic agents and their in vitro activities against the full spectrum of species isolated from bite wounds is needed to help guide therapeutic choices.The use of fluoroquinolones, such as ciprofloxacin and ofloxacin (6,16), for treating bite wound infections has been considered. They have been noted to be active against the aerobic but not many of the anaerobic bacteria isolated from human and animal bite wounds (6, 16). Consequently, there is interest in the potential utility of other quinolones. Sparfloxacin (AT-4140, RP 64206, and PD 131501) is a new fluoroquinolone agent that has an expanded spectrum of activity against aerobic and anaerobic bacteria (1, 4, 7). Temafloxacin, recently voluntarily removed from the market by its manufacturer, was also considered potentially useful in bite wound therapy (5, 7, 10). Erythromycin, while suboptimally active against Pasteurella multocida, must sometimes be used, albeit cautiously, for the treatment of bite wound infections in multidrug-allergic patients, children, and pregnant women. Clarithromycin, a new macrolide, has been noted to have improved pharmacokinetics and in vitro activity compared with those of erythromycin (11,15).Consequently, we determined the comparative susceptibilities of 112 aerobic and 61 anaerobic bite wound isolates to these new antimicrobial agents and compared the activities of these new drugs with those of older agents.All bacteria studied (Table 1) were recent clinical isolates and were identified by standard criteria (2,12,14,18 Strains were taken from frozen stock cultures and transferred twice to ensure purity and good growth. Bacteria were tested by standard procedures by the appropriate methods for the particular organism as previously described (6). Brucella blood agar supplemented with hemin, vitamin K1, and 5% laked sheep blood was the ...

show abstract

In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study

Cited by 10 publications

References 0 publications

New quinolones and gram-positive bacteria

New quinolones and gram-positive bacteria

Fluoroquinolones and Anaerobes

Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents

Contact Info

Product

Resources

About